Fed Circuit split decision denies Biogen’s bid to revive MS drug patent
02-12-2021
Biogen sues Teva over MS generic
18-03-2021
PictureDesignSwiss / Shutterstock.com
Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Biogen, Mylan, The Law Division of the American Chemical Society, the Biotechnology Innovation Organisation, Pharmaceutical Research and Manufacturers
